Fineline Cube

Follow:
14422 Articles
Avenzo Therapeutics Licenses Duality Biologics' EGFR/HER3 Bispecific ADC AVZO-1418/DB-1418
CompanyDeals

Avenzo Therapeutics Licenses Duality Biologics’ EGFR/HER3 Bispecific ADC AVZO-1418/DB-1418

Inceptor Bio and GRIT Biotechnology Partner to Advance CAR-T Therapy IB-T101 for Solid Tumors
CompanyDeals

Inceptor Bio and GRIT Biotechnology Partner to Advance CAR-T Therapy IB-T101 for Solid Tumors

Kexing and Kelun Partner to Expand Overseas Business for Generic Drugs and Therapies
CompanyDeals

Kexing and Kelun Partner to Expand Overseas Business for Generic Drugs and Therapies

PKU 1st Hospital Partners with Baheal Pharmaceutical on Integrin-Targeted Inhibitor Project
CompanyDeals

PKU 1st Hospital Partners with Baheal Pharmaceutical on Integrin-Targeted Inhibitor Project

Takeda and Fudan University's IMI Launch AI-Based Rare Disease Screening and Diagnosis Project
CompanyDeals

Takeda and Fudan University’s IMI Launch AI-Based Rare Disease Screening and Diagnosis Project

LinkedCare Raises Hundreds of Millions in Series E Funding Led by State-Owned Investors
CompanyDeals

LinkedCare Raises Hundreds of Millions in Series E Funding Led by State-Owned Investors

Grand Life Sciences Partners with Cali Biosciences for CPL-01 Commercialization in China
CompanyDeals

Grand Life Sciences Partners with Cali Biosciences for CPL-01 Commercialization in China

Insilico Medicine's ISM5411 Shows Positive Results in Phase I Studies for Inflammatory Bowel Disease
CompanyDrug

Insilico Medicine’s ISM5411 Shows Positive Results in Phase I Studies for Inflammatory Bowel Disease

GlycoNex Licenses SPD8 Biosimilar to Undisclosed Company for Osteoporosis Treatment
CompanyDeals

GlycoNex Licenses SPD8 Biosimilar to Undisclosed Company for Osteoporosis Treatment

Yiling Pharmaceutical Withdraws Clinical Filing for G201-Na in Assisted Reproduction
CompanyDrug

Yiling Pharmaceutical Withdraws Clinical Filing for G201-Na in Assisted Reproduction

China-based Dizal Pharmaceutical Co., Ltd (SHEX: 688192) has announced that its New Drug Application (NDA) for sunvozertinib has been accepted for review by the US FDA with priority review status. The EGFR inhibitor is targeting approval to treat locally advanced or metastatic non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) exon 20 insertion mutations (exon20ins), as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.
CompanyDrug

Dizal’s Sunvozertinib Receives Priority Review from FDA for EGFR Exon 20 NSCLC

Boehringer Ingelheim and Sutro Achieve Commercial-Scale Manufacturing of Luvelta
CompanyDeals

Boehringer Ingelheim and Sutro Achieve Commercial-Scale Manufacturing of Luvelta